Cost-Related Insulin Underuse Among Patients With Diabetes
- PMID: 30508012
- PMCID: PMC6583414
- DOI: 10.1001/jamainternmed.2018.5008
Cost-Related Insulin Underuse Among Patients With Diabetes
Abstract
This survey study examines the association of higher insulin costs with nonadherence in patients with diabetes.
Conflict of interest statement
Comment in
-
When High Prices Mean Needless Death.JAMA Intern Med. 2019 Jan 1;179(1):114-115. doi: 10.1001/jamainternmed.2018.5007. JAMA Intern Med. 2019. PMID: 30508014 No abstract available.
-
Insulin Cost and Underuse in Patients With Diabetes.JAMA Intern Med. 2019 Jun 1;179(6):849. doi: 10.1001/jamainternmed.2019.0973. JAMA Intern Med. 2019. PMID: 31157842 No abstract available.
Similar articles
-
Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.Adv Ther. 2010 Feb;27(2):94-104. doi: 10.1007/s12325-010-0009-6. Epub 2010 Mar 26. Adv Ther. 2010. PMID: 20352392
-
The market in diabetes.Diabetologia. 2006 Feb;49(2):247-52. doi: 10.1007/s00125-005-0108-0. Diabetologia. 2006. PMID: 16416145 No abstract available.
-
Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.Clin Ther. 2007 Jun;29(6 Pt 1):1294-305. doi: 10.1016/j.clinthera.2007.07.007. Clin Ther. 2007. PMID: 18036391
-
[Insulin. A comparison of commercial preparations].Med Monatsschr Pharm. 2006 Mar;29(3):97-100. Med Monatsschr Pharm. 2006. PMID: 16550883 Review. German. No abstract available.
-
Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.Consult Pharm. 2011 Jun;26(6):426-9. doi: 10.4140/TCP.n.2011.426. Consult Pharm. 2011. PMID: 21628141 Review.
Cited by
-
Barriers to WHO prequalification of similar biotherapeutic insulin.Bull World Health Organ. 2024 Nov 1;102(11):795-802. doi: 10.2471/BLT.24.291804. Epub 2024 Sep 25. Bull World Health Organ. 2024. PMID: 39464844 Free PMC article.
-
Taxpayers' Share of US Prescription Drug and Insulin Costs: a Cross-Sectional Study.J Gen Intern Med. 2024 Oct 24. doi: 10.1007/s11606-024-09032-x. Online ahead of print. J Gen Intern Med. 2024. PMID: 39446235
-
Health Outcome Changes in Individuals With Type 1 Diabetes After a State-Level Insulin Copayment Cap.JAMA Netw Open. 2024 Aug 1;7(8):e2425280. doi: 10.1001/jamanetworkopen.2024.25280. JAMA Netw Open. 2024. PMID: 39141389 Free PMC article.
-
State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization.Health Aff (Millwood). 2024 Aug;43(8):1137-1146. doi: 10.1377/hlthaff.2024.00118. Health Aff (Millwood). 2024. PMID: 39102598
-
Measuring the Influence of Side Effect Expectations, Beliefs, and Incident Side Effects on the Risk for Drug Discontinuation Among Individuals Starting New Medications, a Cross-sectional Study.Patient Prefer Adherence. 2024 May 17;18:979-989. doi: 10.2147/PPA.S451012. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38774475 Free PMC article.
References
-
- World Health Organization, Essential Medicines and Health Products, available at: http://www.who.int/medicines/services/essmedicines_def/en/. Accessed October 2, 2018.
-
- Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384-391. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
